Skip Navigation


JAC Advance Access originally published online on January 13, 2005
Journal of Antimicrobial Chemotherapy 2005 55(2):200-208; doi:10.1093/jac/dkh540
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/2/200    most recent
dkh540v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morrissey, I.
Right arrow Articles by Brown, D. F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morrissey, I.
Right arrow Articles by Brown, D. F. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.55 no.2 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved

Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods

Ian Morrissey1, Marion Robbins1, Louise Viljoen1 and Derek F. J. Brown2

1 GR Micro Ltd, 7–9 William Road, London NW1 3ER; 2 Clinical Microbiology and Public Health Laboratory, Health Protection Agency, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QW, UK


* Corresponding author. Tel: +44-20-7388-7320; Fax: +44-20-7388-7324; Email: i.morrissey{at}grmicro.co.uk

Objectives:

To determine the antimicrobial susceptibility of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae causing community-acquired lower respiratory tract infection in the UK during 2002/2003 and to compare susceptibilities determined locally by disc diffusion with agar dilution MICs determined at a central laboratory.

Methods:

H. influenzae, M. catarrhalis and S. pneumoniae were isolated in 30 laboratories and susceptibility determined locally by the BSAC standardized disc diffusion method. At a central laboratory, isolates were re-identified, tested for ß-lactamase production (H. influenzae and M. catarrhalis only) and MICs determined using the BSAC agar dilution method.

Results:

Five hundred and eighty-one H. influenzae, 269 M. catarrhalis and 519 S. pneumoniae were collected. Over 93% of M. catarrhalis and nearly 15% of H. influenzae were ß-lactamase positive rendering these sub-populations resistant to aminopenicillins. Overall, the antibacterial susceptibility rates for the isolates were high. However, macrolides showed poor activity against H. influenzae (0.86–1.38% susceptible by disc or MIC methods) and, compared with other antimicrobials, against S. pneumoniae (approximately 88% susceptible). Between 84% and 95% of H. influenzae, M. catarrhalis and S. pneumoniae were susceptible to cefuroxime but all isolates were susceptible to cefotaxime. Eighty-five percent of H. influenzae were susceptible to trimethoprim. The fluoroquinolones were very active against the isolates, with moxifloxacin showing lower MICs than levofloxacin against S. pneumoniae. Susceptibility determined locally by disc diffusion was in general agreement with that determined centrally by agar dilution MIC testing. However, there was one inconsistency with H. influenzae where disc diffusion indicated 22.9% and 46.8% resistance to clarithromycin and erythromycin, respectively but by MIC, only 0.9% and 6.9% were resistant, respectively.

Conclusions:

Rates of resistance within community-acquired respiratory tract isolates were relatively low in the UK, in agreement with other studies. Moxifloxacin was the only antibacterial with over 99% isolates susceptible for each of the three pathogens investigated where breakpoints are available. The comparison between disc susceptibility testing and MIC determination using BSAC methods indicated generally good correlation but has highlighted a methodological problem with macrolides against H. influenzae in particular.

Keywords: susceptibility testing , Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
J. B. Bulitta, C. B. Landersdorfer, M. Kinzig, U. Holzgrabe, and F. Sorgel
New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics
Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3462 - 3471.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
K. Z. Vardakas MD, I. I. Siempos MD, A. Grammatikos MD, Z. Athanassa MD, I. P. Korbila MD, and M. E. Falagas MD DSc
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials
Can. Med. Assoc. J., December 2, 2008; 179(12): 1269 - 1277.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
D. J. Farrell, D. Felmingham, J. Shackcloth, L. Williams, K. Maher, R. Hope, D. M. Livermore, R. C. George, G. Brick, S. Martin, et al.
Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii87 - ii95.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.